


BIOPHARMA SOLUTIONS

Labcorp[®] Plasma Focus[™]



A targeted liquid biopsy test for global clinical trials and CDx development

Receive actionable results even when tissue is unavailable with a 33-gene liquid biopsy test covering FDA-approved and guideline-driven biomarkers for patients with advanced solid cancers. Powered by the PGDx elio[™] plasma focus kit developed under design control to withstand the rigors of the FDA approval process, Labcorp Plasma Focus is now available in our global labs to empower your clinical trial and CDx development.



Sensitive and specific

Highly sensitive and featuring a highly curated gene panel focused on FDA-approved biomarkers



Fast

Sample collection and processing for results in 7-10 days when rapid results are needed[†]



Global availability

Standardized, efficient service leveraging Labcorp's extensive global network

Specification	Labcorp Plasma Focus	
Intended use	For Research Use Only*	
Featured applications	Cohort stratification, clinical trial enrollment	
Genes evaluated	33	
Panel size	0.24 Mb total	
Accepted sample types and input quantities	Whole blood	2 x 10 mL Streck BCT
	Plasma	3-5 mL recommended; 1 mL minimum
	Cell-free DNA	25 ng recommended; 10 ng minimum
Turnaround time	7-10 days on average [†]	
Average total/de-duplicated coverage	30,000x/2,600x	
Variants and biomarkers assessed	SNVs, indels, rearrangements, amplifications, microsatellite instability (MSI)	
Variant Allele Frequency (VAF) to report	0.1% (select actionable); 0.5% (all bases)	
Indel detection	Up to 42 bp insertions and deletions	
Sample pass rate	96%	
Data processing workflow	Single automated pipeline; custom analysis available	
Data reported	Standard trial report (customizable upon request) Supplementary files available upon request	

Full coding region for 33 genes:			
AKT1	CHH1	MYC	●
ALK	◇	CSF1R	
APC	EGFR	●	◇
ARID1AC	ERBB2	●	
ATM	EZH2		
BRAF	FGFR1		
BRCA1	FGFR2	●	◇
BRCA2	HRAS		
BRIP1	KIT	●	◇
CCND1	KRAS		◇
CD274	MET	●	
			TP53

Gene list

Labcorp Plasma Focus targets 33 actionable genes for somatic SNVs and indels, amplifications in 8 genes, fusions in 5 genes, and detects microsatellite instability (MSI).

- Amplifications
- ◇ Translocations



Global Biopharma Service

Now available from Labcorp-owned and -operated sites in Baltimore, U.S.; Geneva, Switzerland and Shanghai, China

WHY LABCORP

One lab partner to achieve your next cancer breakthrough

At Labcorp, we provide industry-leading biopharma services and solutions to help you discover, develop and deliver life-changing therapies that increase the potential to save the lives of people around the world. Built on a reputation for scientific and technical excellence and an unmatched global network, we can support you at every stage of the cancer research continuum.



Deep scientific knowledge and experience:

Access comprehensive and specialized oncology expertise with our integrated medical, scientific, regulatory and statistical teams



Development acceleration:

Reduce development time and risk with end-to-end support from discovery through diagnostic commercialization



Data-driven insights:

Optimize biomarker-driven development with unparalleled data and real-world evidence



Global laboratory network:

Enable day-one readiness with global drug and diagnostic codevelopment and test commercialization capabilities



Supported more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, including 86% of those specific to oncology



Experience supporting clinical trial testing for 2,000+ trials across various tumor types



More than 60% of all FDA-approved CDx and complementary diagnostic assays in the market

Contact our biopharma team to see how we can help you accelerate your precision oncology program.

Learn more at oncology.labcorp.com/biopharma-partners

